Description: ViroGates A/S, a medical technology company, develops and markets prognostic products for the healthcare sector. It offers suPARnostic, a blood test that measures the soluble urokinase plasminogen activator receptor (suPAR) protein in the bloodstream used for emergency departments in hospitals to improve clinical decisions on hospitalization or discharge of acute medical patients and reduce healthcare cost. The company also provides suPARnostic TurbiLatex, a latex particle-enhanced turbidimetric immunoassay that quantitatively determines the suPAR level in human K2-EDTA- or lithium heparin plasma samples; suPARnostic Quick Triage kit, which is used in the point of care situation for early warning and patient triaging; and suPARnostic ELISA that provides fully quantitative results. Its suPAR prognostic tool used in various diseases, such as cardiovascular, kidney, cancer, diabetes, liver, infectious, respiratory, and rheumatic. The company was incorporated in 2000 and is headquartered in Birkerød, Denmark.
Home Page: www.virogates.com
BanevAenget 13
Birkerød,
3460
Denmark
Phone:
45 21 13 13 36
Officers
| Name | Title |
|---|---|
| Mr. Jakob Knudsen | Chief Exec. Officer |
| Dr. Jesper Eugen-Olsen | Co-Founder & Chief Scientific Officer |
| Mr. Mark Christian Hvidberg da Silva | Chief Financial Officer |
| Ms. May Britt Dyvelkov | VP of Accounting |
| Mr. Thomas Krarup | VP of Global Sales & Marketing |
Exchange: CO
Country: DK : Denmark
Currency: Danish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.494 |
| Price-to-Sales TTM: | 16.3833 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 10 |